A pretargeted PET imaging strategy based on bioorthogonal diels-alder click chemistry

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1389-1396

  Zeglis, Brian M ^a   Sevak, Kuntal K ^a   Reiner, Thomas ^a   Mohindra, Priya ^a   Carlin, Sean D ^a   Zanzonico, Pat ^a   Weissleder, Ralph ^b   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antibody; Click chemistry; Colorectal cancer; Positron emission tomography (PET); Pretargeting

Indexed keywords

RADIOISOTOPE; RADIOLIGAND; TETRAZINE DERIVATIVE; TRANSCYCLOOCTENE; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CLICK CHEMISTRY; COLORECTAL CANCER; CYCLOADDITION; DIELS ALDER REACTION; DOSIMETRY; FECES; HUMAN; IMMUNOREACTIVITY; IN VIVO STUDY; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; XENOGRAFT;

ANTIBODY; CLICK CHEMISTRY; COLORECTAL CANCER; POSITRON EMISSION TOMOGRAPHY (PET); PRETARGETING;

ANIMALS; ANTIBODIES; CELL LINE, TUMOR; CLICK CHEMISTRY; COPPER RADIOISOTOPES; CYCLOOCTANES; HETEROCYCLIC COMPOUNDS; HUMANS; MICE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS;

EID: 84881407469     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.115840     Document Type: Article

References (25)

1. Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50:2-5.
2. Zeglis B, Lewis JS. A practical guide to the construction of radiometallation bioconjugates for positron emission tomography. Dalton Trans. 2011;40: 6168-6195.
3. Hollander N. Bispecific antibodies for cancer therapy. Immunotherapy. 2009;1: 211-222.
4. Sharkey RM, Goldenberg DM. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest. 2006;24:82-97.
5. Boerman OC, van Schaijk FG, Oyen WJG, Corstens FHM. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med. 2003;44:400-411.
6. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
7. Goldenberg DM, Chang CH, Rossi EA, McBride WJ, Sharkey RM. Pretargeted molecular imaging and radioimmunotherapy. Theranostics. 2012;2:523-540.
8. Liu G, Dou S, Liu Y, Wang Y, Rusckowski M, Hnatowich DJ. 90Y-labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy. Bioconjug Chem. 2011;22:2539-2545.
9. Lewis MR, Wang M, Axworthy DB, et al. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med. 2003;44:1284-1292.
10. Mohsin H, Jia F, Bryan JN, et al. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu. Bioconjug Chem. 2011;22:2444-2452.
11. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed Engl. 2001;40:2004-2021.
12. Sletten EM, Bertozzi CR. Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. Angew Chem Int Ed Engl. 2009;48:6973-6998.
13. Devaraj NK, Upadhyay R, Hatin JB, Hilderbrand SA, Weissleder R. Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans- cyclooctene cycloaddition. Angew Chem Int Ed Engl. 2009;48:7013-7016.
14. Blackman ML, Royzen M, Fox JM. Tetrazine ligation: fast bioconjugation based on inverse electron demand Diels-Alder reactivity. J Am Chem Soc. 2008;130: 13518-13519.
15. Zeglis BM, Mohindra P, Weissmann GI, et al. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjug Chem. 2011;22: 2048-2059.
16. Li Z, Cai H, Hassink M, et al. Tetrazine-trans-cyclooctene ligation for the rapid construction of 18-F labeled probes. Chem Commun (Camb). 2010;46:8043-8045.
17. Reiner T, Keliher EJ, Earley S, Marinelli B, Weissleder R. Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. Angew Chem Int Ed Engl. 2011; 50:1922-1925.
18. Rossin R, Verkerk PR, van den Bosch SM, et al. In vivo chemistry for pretargeted tumor imaging in live mice. Angew Chem Int Ed Engl. 2010;49:3375-3378.
19. Devaraj NK, Thurber GM, Keliher EJ, Marinelli B, Weissleder R. Reactive polymer enables efficient in vivo bioorthogonal chemistry. Proc Natl Acad Sci USA. 2012;109:4762-4767.
20. Carrasquillo JA, Pandi-Taskar N, O'Donoghue JA, et al. 124I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011;52:1173-1180.
21. Ackerman ME, Chalouni C, Schmidt MM, et al. A33 antigen displays persistent surface expression. Cancer Immunol Immunother. 2008;57:1017-1027.
22. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858-2902.
23. Heneweer C, Holland JP, Divilov V, Carlin S, Lewis JS. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: Zr-89-albumin as a model system. J Nucl Med. 2011;52:625-633.
24. Stabin MG, Sarks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
25. Welt S, Scott AM, Divgi CR, et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1996;14:1787-1797.